Stifel Reiterates Buy Rating on Evolus (EOLS)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq futures jump 2% as Micron, Qualcomm forecasts ease AI concerns; PCE data awaited
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company’s Guidance
January 21, 2025 8:00 AM ESTExpects U.S. Approval Within 90 Days for Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels
Provides 2025 Guidance and Maintains Projection for Full-Year 2025 Profitability1
Preliminary Unaudited Net Revenue of $79.0 Million for the Fourth Quarter 2024, Representing 30% Growth Over the Prior Year Preliminary Unaudited Net Revenue of $266.3 Million for the Full-Year 2024, Representing 32% Growth Over the Prior Year and at the Top of the Companys Guidance Expects U.S. Food and Drug Administration (FDA) Approval Within 90 Days for Evolysse Form and Evolysse Smooth Injectable... MoreEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 17, 2025 4:05 PM ESTNEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in January of an aggregate of 15,332 restricted stock units (RSUs) of the companys common stock to 6 newly hired... More
